143 related articles for article (PubMed ID: 4054715)
21. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
Stewart DJ; Nundy D; Maroun JA; Tetreault L; Prior J
Cancer Treat Rep; 1985 Mar; 69(3):269-73. PubMed ID: 3884152
[TBL] [Abstract][Full Text] [Related]
22. Preliminary study of the combination, dianhydrogalactitol, cis-diaminedichloroplatinum (II), and VP-16-213 in patients with advanced cancer.
Creagan ET; Eagan RT; Kvols LK
Oncology; 1981; 38(5):260-1. PubMed ID: 7196561
[TBL] [Abstract][Full Text] [Related]
23. [Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].
Konishi I; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
Gan To Kagaku Ryoho; 1985 Jul; 12(7):1482-6. PubMed ID: 4015122
[TBL] [Abstract][Full Text] [Related]
24. [A phase II clinical trial of oral VP 16-213 in advanced non-Hodgkin's lymphoma].
Nakada H; Ogawa M; Ingaki J; Horikoshi N; Inoue K; Usui N; Adachi K; Tada A; Yamazaki H; Mukaiyama T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1644-8. PubMed ID: 6476837
[TBL] [Abstract][Full Text] [Related]
25. [Collaborative phase II study of etoposide (NK-171). Urological Cooperative Study Group of etoposide (NK-171)].
Gan No Rinsho; 1985 Jul; 31(8):944-52. PubMed ID: 4040986
[TBL] [Abstract][Full Text] [Related]
26. [Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
Suzuki K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2772-9. PubMed ID: 3753024
[TBL] [Abstract][Full Text] [Related]
27. [The value of etoposide (VP-16) in the therapy of refractory ovarian cancer].
Marth C; Pointner E; Zeimet AG; Abfalter E; Koza A; Windbichler G; Hetzel H; Dapunt O
Geburtshilfe Frauenheilkd; 1993 May; 53(5):303-7. PubMed ID: 8514100
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.
Slayton RE; Creasman WT; Petty W; Bundy B; Blessing JA
Cancer Treat Rep; 1979; 63(11-12):2089-92. PubMed ID: 526942
[No Abstract] [Full Text] [Related]
29. [Phase II study of etoposide (NK 171) in advanced hematological malignancies].
Yoshida T; Nakanishi J; Ito K; Kobayashi S; Ohtake S; Nakamura S; Hattori K
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1579-84. PubMed ID: 6476835
[TBL] [Abstract][Full Text] [Related]
30. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.
Markman M; Blessing JA; Major F; Manetta A
Gynecol Oncol; 1993 Aug; 50(2):191-5. PubMed ID: 8375734
[TBL] [Abstract][Full Text] [Related]
31. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Rose PG; Blessing JA; Mayer AR; Homesley HD
J Clin Oncol; 1998 Feb; 16(2):405-10. PubMed ID: 9469322
[TBL] [Abstract][Full Text] [Related]
32. cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma.
Veronesi A; Zagonel V; Santarossa M; Tirelli U; Galligioni E; Trovo' MG; Tumolo S; Grigoletto E
Cancer Chemother Pharmacol; 1983; 11(1):35-7. PubMed ID: 6683999
[TBL] [Abstract][Full Text] [Related]
33. Treatment for recurrent ovarian cancer. A report of 2 cases.
Maxwell AM; Jordaan JP
S Afr Med J; 1987 Feb; 71(3):180. PubMed ID: 3810370
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
[TBL] [Abstract][Full Text] [Related]
35. Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study.
Eckhardt S; Hernádi Z; Thurzó L; Telekes A; Sopkova B; Mechl Z; Pawlicki M; Kerpel-Fronius S
Oncology; 1990; 47(4):289-95. PubMed ID: 2195412
[TBL] [Abstract][Full Text] [Related]
36. [Phase I study of an oral administration of VP 16-213].
Ogawa M; Ota K; Oyama A; Fukuoka M; Takada M; Yoshida S; Sanpi K; Kimura I; Ohnoshi T; Kuraishi Y
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2403-7. PubMed ID: 6639102
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of a new form of an oral administration of VP-16-213.
Lau ME; Hansen HH; Nissen NI; Pedersen H
Cancer Treat Rep; 1979 Mar; 63(3):485-7. PubMed ID: 371801
[TBL] [Abstract][Full Text] [Related]
38. cis-Dichlorodiammineplatinum (II) and hexamethylmelamine in advanced ovarian carcinoma: a phase II study.
Lund B; Aabo K; Rørth M; Hansen HH
Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1089-92. PubMed ID: 6819145
[TBL] [Abstract][Full Text] [Related]
39. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.
Cavalli F; Sonntag RW; Jungi F; Senn HJ; Brunner KW
Cancer Treat Rep; 1978 Mar; 62(3):473-5. PubMed ID: 348319
[No Abstract] [Full Text] [Related]
40. Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.
Vaughn CB; Panettiere F; Thigpen T; Bottomley R; Hoogstraten B; Samal B
Cancer Treat Rep; 1981; 65(5-6):443-5. PubMed ID: 7237465
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
